Khattab F, et al. - Researchers conducted the study for comparing the effectiveness and safety of intradermal Botulinum toxin (BTX) in the treatment of plaque psoriasis. A comparative study carried out in 35 patients with chronic plaque psoriasis was treated by split-body therapy. The patients were given either intradermal BTX or intralesional 5-fluorouracil (5 FU) to each of 2 bilaterally symmetrical psoriatic plaque lesions. The response rate was 85% on the BTX treatment side and 90% on the 5-FU side at the end of the study. The authors concluded that BTX was a novel, safe, single injection, and effective therapy for plaque-type psoriasis. More research is needed to prove the efficacy of BTX in the treatment of plaque psoriasis.